Search company, investor...
The Cumberland company logo

The Cumberland

cumberland.co.uk

Founded Year

1850

About The Cumberland

The Cumberland is a building society that provides services such as mortgages, savings, current accounts, and other financial services. The company is based in Cumbria, England.

Headquarters Location

Cooper Way

Cumbria, England, 3 0JF,

United Kingdom

Missing: The Cumberland's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: The Cumberland's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

The Cumberland Patents

The Cumberland has filed 1 patent.

The 3 most popular patent topics include:

  • Astrobiology
  • NASA space probes
  • Planetary habitability
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/19/2017

8/25/2020

Astrobiology, Transiting exoplanets, Planetary habitability, Proposed space probes, NASA space probes

Grant

Application Date

5/19/2017

Grant Date

8/25/2020

Title

Related Topics

Astrobiology, Transiting exoplanets, Planetary habitability, Proposed space probes, NASA space probes

Status

Grant

Latest The Cumberland News

RS BioTherapeutics Selects Recipharm as Product Characterization Partner

Nov 14, 2022

Cumberland, Maryland, UNITED STATES CUMBERLAND, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce that is has selected Recipharm, a leading Contract Development and Manufacturing Organization (CDMO), as its partner to conduct product characterization for its investigational compound, RSBT-001. Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD). Commenting on the partnership, Justin Molignoni, Chief Strategy Officer of RS BioTherapeutics said, “We are very pleased to partner with Recipharm for product characterization testing to support the development of RSBT-001 as a treatment for COPD. Recipharm is one of the world’s leading pharmaceutical Contract Development and Manufacturing Organizations (CDMOs) that is actively involved in the development of therapeutics for pulmonary and systemic diseases. We are excited to leverage their experience and expertise.” Chris Hirst, Head of Recipharm’s Advanced Delivery Systems Business Unit said, “Recipharm is delighted to be working with RS BioTherapeutics, providing product characterization testing to support the development of RSBT-001. We look forward to being able to support RS BioTherapeutics’ understanding of the endocannabinoid system as it drives to commercialize new therapies for chronic and acute pulmonary inflammation-based diseases.” In July, RS BioTherapeutics announced positive results from its proof-of-concept study with its development partner Synthonics and Marshall University, for RSBT-001. RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. About RS BioTherapeutics Founded by experts in pulmonary diseases and the endocannabinoid system, RS BioTherapeutics is a wholly owned subsidiary of Real Science Holdco LLC. The company’s mission is to harness its strong and thorough understanding of the Endocannabinoid System in the research, development, and commercialization of forward-thinking interventions to address chronic and acute pulmonary inflammation-based diseases. More information on RS BioTherapeutics can be found at www.rsbiotherapeutics.com . About Recipharm Recipharm is a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and its services, please visit www.recipharm.com . Media Contacts:

The Cumberland Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

The Cumberland Rank

The Cumberland Frequently Asked Questions (FAQ)

  • When was The Cumberland founded?

    The Cumberland was founded in 1850.

  • Where is The Cumberland's headquarters?

    The Cumberland's headquarters is located at Cooper Way, Cumbria.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.